CANINE VACCINATION PROTOCOL
– 2004
MINIMAL VACCINE USE
W. Jean Dodds, DVM
HEMOPET
938 Stanford Street
Santa Monica, CA 90403
310-828-4804; Fax 310-828-8251
e-mail: hemopet@hotmail.com
Note: The following vaccine protocol
is offered for those dogs where minimal vaccinations are advisable or desirable.
The schedule is one I recommend and should not be interpreted to mean that
other protocols recommended by a veterinarian would be less satisfactory.
It's a matter of professional judgment and choice.
9 - 10 weeks - Distemper + Parvovirus,
MLV (e.g. Intervet Progard Puppy DPV)
14 weeks - Same as above
16 -18 weeks (optional) - Same
as above
20 weeks or older, if allowable by
law - Rabies
1 year - Distemper + Parvovirus,
MLV
1 year - Rabies, killed 3-year product
(give 3-4 weeks apart from distemper/parvovirus booster)
Perform vaccine antibody titers for
distemper and parvovirus annually thereafter. Vaccinate for rabies virus
according to the law, except where circumstances indicate that a written
waiver needs to be obtained from the primary care veterinarian. In
that case, a rabies antibody titer can also be performed to accompany the
waiver request.
ADVERSE
VACCINE REACTIONS
W. Jean Dodds, DVM
Hemopet/Hemolife
938 Stanford Street
Santa Monica, CA 90403
310-828-4804; Fax 310-828-8251
Viral disease and recent vaccination
with single or combination modified live-virus (MLV) vaccines, especially
those containing distemper virus, adenovirus 1 or 2, and parvovirus are
increasingly recognized contributors to immune-mediated blood disease,
bone marrow failure, and organ dysfunction. 1-11
Potent adjuvanted killed vaccines like those for rabies virus
also can trigger immediate and delayed (vaccinosis) adverse vaccine reactions.7-10
Genetic predisposition to these disorders in humans has been linked to
the leucocyte antigen D-related gene locus of the major histocompatibility
complex, and is likely to have parallel associations in domestic animals.
5,
7
Beyond immediate hypersensivity reactions,
other acute events tend to occur 24-72 hours afterwards, or 7-45 days later
in a delayed type immunological response. 1-4, 6-10
Even more delayed adverse effects include mortality from high-titered measles
vaccine in infants, canine distemper antibodies in joint diseases
of dogs, and feline injection-site fibrosarcomas.
5,7 The increasing antigenic load presented to the
host individual by modified-live virus (MLV) vaccines during the period
of viremia is presumed to be responsible for the immunological challenge
that can result in a delayed hypersensitivity reaction. 2,
3, 6, 7
The clinical signs associated with
vaccine reactions typically include fever, stiffness, sore joints and abdominal
tenderness, susceptibility to infections, neurological disorders and encephalitis,
collapse with autoagglutinated red blood cells and icterus (autoimmune
hemolytic anemia) (AIHA), or generalized petechiae and ecchymotic hemorrhages
(immune-mediated thrombocytopenia)(ITP).1, 2, 4, 7,
8, 12, 13 Hepatic enzymes may be markedly elevated,
and liver or kidney failure may occur by itself or accompany bone marrow
suppression. Furthermore, MLV vaccination has been associated with
the development of transient seizures in puppies and adult dogs of breeds
or cross-breeds susceptible to immune-mediated diseases especially those
involving hematologic or endocrine tissues (e.g. AIHA, ITP, autoimmune
thyroiditis). 1,7,10 Post-vaccinal
polyneuropathy is a recognized entity associated occasionally with the
use of distemper, parvovirus, rabies and presumably other vaccines. 2,
3, 7 This can result in various clinical
signs including muscular atrophy, inhibition or interruption of neuronal
control of tissue and organ function, muscular excitation, incoordination
and weakness, as well as seizures. 7 Certain
breeds or families of dogs appear to be more susceptible to adverse vaccine
reactions, particularly post-vaccinal seizures, high fevers, and painful
episodes of hypertrophic osteodystrophy (HOD).7, 9
Therefore, we have the responsibility to advise companion animal breeders
and caregivers of the potential for genetically susceptible littermates
and relatives to be at increased risk for similar adverse vaccine reactions.1,
4, 6-9, 14-17 In popular (or rare) inbred and
linebred animals, the breed in general can be at increased risk as illustrated
in the examples below.
Commercial vaccines can on rare occasion
be contaminated with other adventitious viral agents, 3,
15 which can produce significant untoward effects
such as occurred when a commercial canine parvovirus vaccine was contaminated
by blue tongue virus. It produced abortion and death when given to pregnant
dogs,15 and was linked causally
to the ill-advised but all too common practice of vaccinating pregnant
animals. The potential for side-effects such as promotion of chronic disease
states in male and non-pregnant female dogs receiving this lot of
vaccine remains in question, although there have been anecdotal reports
of reduced stamina and renal dysfunction in performance sled dogs. 17
Recently, a vaccine manufacturer had to recall all biologic products
containing a distemper component, because they were associated with a higher
than expected rate of central nervous system postvaccinal reactions 1-2
weeks following administration. 17
Other issues arise from overvaccination,
as the increased cost in time and dollars spent needs to be considered,
despite the well-intentioned solicitation of clients to encourage annual
booster vaccinations so that pets also can receive a wellness examination.6
Giving annual boosters when they are not necessary has the client paying
for a service which is likely to be of little benefit to the pet’s existing
level of protection against these infectious diseases. It also increases
the risk of adverse reactions from the repeated exposure to foreign
substances.
Polyvalent MLV vaccines which multiply
in the host elicit a stronger antigenic challenge to the animal and should
mount a more effective and sustained immune response. 2,
3, 6 However, this can overwhelm the immunocompromised
or even a healthy host that has ongoing exposure to other environmental
stimuli as well as a genetic predisposition that promotes adverse response
to viral challenge. 1, 2, 7, 14, 16, 17
The recently weaned young puppy or kitten being placed in a new environment
may be at particular risk. Furthermore, while the frequency of vaccinations
is usually spaced 2-3 weeks apart, some veterinarians have advocated vaccination
once a week in stressful situations, a practice makes little sense scientifically
or medically.6
An augmented immune response to vaccination
is seen in dogs with pre-existing inhalant allergies (atopy) to pollens.
7 Furthermore, the increasing
current problems with allergic and immunological diseases has been linked
to the introduction of MLV vaccines more than 20 years ago. 3
While other environmental factors no doubt have a contributing role, the
introduction of these vaccine antigens and their environmental shedding
may provide the final insult that exceeds the immunological tolerance threshold
of some individuals in the pet population. The accumulated evidence
indicates that vaccination protocols should no longer be considered as
a “one size fits all” program.
9
For these special cases, appropriate
alternatives to current vaccine practices include: measuring serum antibody
titers; avoidance of unnecessary vaccines or overvaccinating; caution in
vaccinating sick or febrile individuals; and tailoring a specific minimal
vaccination protocol for dogs of breeds or families known to be at increased
risk for adverse reactions.6,7,18
Considerations include starting the vaccination series later, such as at
nine or ten weeks of age when the immune system is more able to handle
antigenic challenge; alerting the caregiver to pay particular attention
to the puppy’s behavior and overall health after the second or subsequent
boosters; and avoiding revaccination of individuals already experiencing
a significant adverse event. Littermates of affected puppies should be
closely monitored after receiving additional vaccines in a puppy series,
as they too are at higher risk.
References
1. Dodds WJ. Immune-mediated diseases
of the blood. Adv Vet Sci Comp Med 1983; 27:163-196.
2. Phillips TR, Jensen JL, Rubino
MJ, Yang WC, Schultz RD. Effects on vaccines on the canine immune
system. Can J Vet Res 1989; 53: 154-160.
3. Tizard I. Risks associated with
use of live vaccines. J Am Vet Med Assoc 1990; 196:1851-1858.
4. Duval D, Giger U. Vaccine-associated
immune-mediated hemolytic anemia in the dog. J Vet Int Med 1996;10: 290-295.
5. Cohen AD, Shoenfeld Y. Vaccine-induced
autoimmunity. J Autoimmunity 1996; 9: 699-703.
6. Schultz R. Current and future
canine and feline vaccination programs. Vet Med 1998; 93:233-254.
7. Dodds WJ. More bumps on the vaccine
road. Adv Vet Med 1999; 41: 715-732.
8. HogenEsch H, Azcona-Olivera J,
Scott-Moncrieff C, Snyder PW, Glickman LT. Vaccine-induced autoimmunity
in the dog. Adv Vet Med 1999; 41:733-744.
9. Dodds WJ. Vaccination protocols
for dogs predisposed to vaccine reactions. J Am An Hosp Assoc 2001; 38:
1-4.
10. Scott-Moncrieff JC, Azcona-Olivera
J, Glickman NW, Glickman LT, HogenEsch H. Evaluation of antithyroglobulin
antibodies after routine vaccination in pet and research dogs. J Am Vet
Med Assoc 2002; 221: 515-521.
11. Paul MA (chair) et al. Report
of the AAHA Canine Vaccine Task Force: 2003 canine vaccine guidelines,
recommendations, and supporting literature. AAHA, April 2003, 28 pp.
12. May C, Hammill J, Bennett, D.
Chinese shar pei fever syndrome: A preliminary report. Vet Rec 1992;131:
586-587.
13. Scott-Moncrieff JC, Snyder PW,
Glickman LT, Davis EL, Felsburg PJ. Systemic necrotizing vasculitis
in nine young beagles. J Am Vet Med Assoc 1992; 201: 1553-1558.
14. Dodds WJ. Estimating disease
prevalence with health surveys and genetic screening. Adv Vet Sci Comp
Med 1995; 39: 29-96.
15. Wilbur LA, Evermann JF, Levings
RL, Stoll LR, Starling DE, Spillers CA, Gustafson GA, McKeirnan AJ.
Abortion and death in pregnant bitches associated with a canine vaccine
contaminated with blue tongue virus. J Am Vet Med Assoc 1994; 204:1762-1765.
16. Day MJ, Penhale WJ. Immune-mediated
disease in the old English sheepdog. Res Vet Sci 1992; 53: 87-92.
17. Dougherty SA, Center SA. Juvenile
onset polyarthritis in Akitas. J Am Vet Med Assoc 1991; 198: 849-855.
18. Twark L, Dodds WJ. Clinical
use of serum parvovirus and distemper virus antibody titers for determining
revaccination strategies in healthy dogs. J Am Vet Med Assoc 2000; 217:1021-1024.
The
Pet Advocates Town Hall